- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - May 28, 2013 P1, N=13, Recruiting, Suspended --> Completed N=18 --> 13
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer (clinicaltrials.gov) - Jan 15, 2013 P2, N=46, Active, not recruiting, Completed --> Terminated; Administratively complete. Completed --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Jan 7, 2013 P1/2, N=43, Active, not recruiting, N=24 --> 30 Recruiting --> Active, not recruiting
- |||||||||| erlotinib / Generic mfg., docetaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jun 13, 2012 P1/2, N=30, Completed, Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| oxaliplatin / Generic mfg., cisplatin / Generic mfg., capecitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer. (clinicaltrials.gov) - May 20, 2012 P2, N=25, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
|